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Abstract
Background: Healthcare provider (HCP) activities and attitudes towards patients strongly influence medication
adherence. The aim of this study was to assess current clinical practices to support patients in adhering to
treatment with oral anticancer agents (OACA) and to explore clues to improve the management of medication
adherence.
Methods: A cross-sectional, observational study among HCPs in (haemato-)oncology settings in Belgium and the
Netherlands was conducted in 2014 using a composite questionnaire. A total of 47 care activities were listed and
categorised into eight domains. HCPs were also asked about their perceptions of adherence management on the
items: insight into adherence, patients’ communication, capability to influence, knowledge of consequences and insight
into causes. Validated questionnaires were used to assess beliefs about medication (BMQ) and shared decision
making (SDM-Q-doc).
Results: In total, 208 HCPs (29% male) participated; 107 from 51 Dutch and 101 from 26 Belgian hospitals. Though
a wide range of activities were reported, certain domains concerning medication adherence management received
less attention. Activities related to patient knowledge and adverse event management were reported most
frequently, whereas activities aimed at patient’s self-efficacy and medication adherence during ongoing use were
frequently missed. The care provided differed between professions and by country. Belgian physicians reported
more activities than Dutch physicians, whereas Dutch nurses and pharmacists reported more activities than Belgian
colleagues. The perceptions of medication adherence management were related to the level of care provided by
HCPs. SDM and BMQ outcomes were not related to the care provided.
Conclusions: Enhancing the awareness and perceptions of medication adherence management of HCPs is likely to
have a positive effect on care quality. Care can be improved by addressing medication adherence more directly e.g.,
by questioning patients about (expected) barriers and discussing strategies to overcome them, by asking for missed
doses and offering (electronic) reminders to support long-term medication adherence. A multidisciplinary approach is
recommended in which the role of the pharmacist could be expanded.
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Background
Due to the availability of rapidly growing numbers of
new oral anticancer agents (OACA) directed towards
specific tumour cell targets, in (haemato-)oncology
medication adherence is becoming an increasingly im-
portant issue [1]. Oral administration may improve qual-
ity of life by its convenience and ease of use. Provided
that efficacy and toxicity are at least similar to the effects
of IV treatment, most patients therefore prefer treatment
with OACA [2, 3].
Non-adherence to medication is a complex and multi-
dimensional healthcare problem. Adherence is defined
as the extent to which a patient follows agreed recom-
mendations for prescribed treatments [4]. Patients may
intentionally or unintentionally be non-adherent during
different stages of their treatment [5, 6]. Adherence to
long-term therapies in chronic diseases is estimated at
50–70% [4, 7]. Regarding adherence to OACA, rates be-
tween 16 and 100% have been reported [8].
For the individual patient non-adherence may have ser-
ious consequences (e.g., lack of efficacy or increased tox-
icity) while society may face increased healthcare costs [1].
The minimum level of adherence required to achieve a
positive clinical outcome (the so called ‘drug forgiveness’),
varies by drug and is often not exactly known. Research
on adherence to protein kinase inhibitor treatment in pa-
tients with chronic myeloid leukaemia (CML) revealed the
existence of a strong relationship between the missing of
only a small number of doses per month (5%) and a less
favourable clinical outcome [9].
Factors influencing adherence are numerous [10, 11].
The WHO framework elaborately describes the multidi-
mensional phenomenon of medication adherence [4]. It
includes five interacting dimensions that influence ad-
herence: social and economic factors, condition-related
factors, therapy-related factors, patient-related factors,
and healthcare provider (HCP) and system-related fac-
tors. Few studies have been published on HCP-related
factors influencing medication adherence in (haemato-
)oncology. In patients with breast cancer on chronic
endocrine therapy, a poor physician’s explanation of
treatment effects was related to non-adherence [12]. In
addition, patients with CML on long-term imatinib
treatment reported that positive feedback from physi-
cians reinforced the belief that ‘occasional’ non-
adherence would not affect efficacy [13]. More generally,
it appeared that HCPs’ beliefs about OACA affected
their behaviour and care attitude which in turn influ-
enced the adherence behaviour of patients [13].
HCPs’ beliefs about OACA and their use, HCPs’ percep-
tions of OACA adherence management and in the case of
physicians their perceptions of shared decision making,
were explored in the first part of this study which was pub-
lished separately [14]. Most HCPs considered themselves
to have adequate knowledge of the causes and conse-
quences of non-adherence and felt able to influence the
medication adherence of their patients. However, several
HCPs, nurses and pharmacists in particular, appeared to
have no information on the actual adherence of their pa-
tients, nor did they thought that their patients were willing
to discuss adherence with them. Unfortunately, it remained
unclear to what extent these findings were related to the
care that was provided.
In supporting patients to adhere to their medication
HCPs must create several preconditions for adherent be-
haviour [15, 16]. In this respect, patients need to be aware
of the existence and consequences of non-adherence and
need to be convinced that they have the capacity to man-
age their treatment themselves (self-efficacy). In addition,
they must have been given clear instructions on how to
use the prescribed medication and must be able to cor-
rectly use the medication. Knowledge of their disease and
treatment is therefore also needed as well as social sup-
port, adverse event management instructions and removal
of all possible barriers to the optimal use of OACA.
The aim of this study was to explore current clinical
practices of supporting adherence to treatment with
OACA in Belgium and the Netherlands and to find clues
for improvement of care. Furthermore, the relationship
between HCPs’ beliefs and the supportive care HCPs
provide have been explored.
Methods
Study design
Using a cross-sectional observational design, the present
study was conducted in the period April - October 2014
in the Netherlands and Belgium. HCPs with the profes-
sion of medical oncologist, haematologist, nurse practi-
tioner (NP), nurse or pharmacist, and providing patient
care in a (haemato-)oncology setting in the Netherlands
or Dutch-speaking part of Belgium, were asked to fill
out a questionnaire.
Data collection procedure
HCPs were invited by their professional associations to
fill out an electronic questionnaire available in the form
of a secure internet-link. The professional associations
that spread the link to their members were the NVMO,
HOVON, NVALT, V&VN, NVPF in the Netherlands and
the VZA, VVRO, BSMO, BHS in Belgium. The link was
made available either by e-mail and/or publication in an
electronic newsletter. A reminder was sent to stimulate
response. Additional recruitment took place by distribut-
ing the internet-link within the authors’ network, and by
handing out a paper version of the questionnaire at a
scientific meeting on adherence to OACA treatment,
held on the 13th of October 2014 in Brussels. The partic-
ipants completed the questionnaire anonymously.
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Questionnaire
A composite questionnaire was used, starting with personal
characteristics of the respondents i.e., profession, gender,
number of years employed, hospital and specialization. The
questionnaire consisted of four parts: 1) Perceptions of ad-
herence management, 2) Shared decision making (SDM),
3) Beliefs about OACA, and 4) Care usually provided (usual
care (UC)) in supporting adherence to treatment with
OACA. As respondents were not able to give multiple an-
swers for different patient groups, they were asked to
complete the questionnaire in relationship to their main pa-
tient group (the patient group they treat most frequently).
The questionnaire was pilot-tested by nine HCPs (i.e., a
medical oncologist, a haematologist, three nurse practi-
tioners, three pharmacists, and a general practitioner) in
Belgium and the Netherlands. In individual interviews it
was explored whether the items were understood as
intended. The pilot-HCPs were also asked about items of
care activities to support medication adherence and to add
items if anything was missing. After processing the com-
ments, the final version of the questionnaire was defined.
1. Perceptions of medication adherence management
To assess HCPs’ perceptions of medication
adherence management, five questions were
formulated: (1) Insight into adherence: I know the
level of adherence of all my patients; (2) Patients’
communication: I think that patients discuss non-
adherence with me, (3) Capability to influence: I am
able to influence adherence behaviour of my pa-
tients, (4) Knowledge of consequences: I have suffi-
cient knowledge of the consequences of non-
adherence, and (5) Insight into causes: I have suffi-
cient knowledge of the causes of non-adherence to
discuss this with patients. Answers were given on a
5-point Likert scale (where 1 = strongly disagree, 2
= disagree, 3 = uncertain, 4 = agree and 5 = strongly
agree). The answers ‘agree’ and ‘strongly agree’ were
dichotomized into ‘yes’ [1] and the remaining an-
swers into ‘no or uncertain’ (0). A sum score of the
Perceptions of Adherence Management Questions
(PAMQs sum score), ranging from zero to five, was
calculated by summing the five dichotomized items.
2. Shared decision making
The validated Shared Decision Making
Questionnaire – physician version (SDM-Q-Doc),
in the authorized Dutch translation, was used [17].
The SDM-Q-Doc consists of nine items that are
rated on a 6-point Likert scale (‘completely disagree’
to ‘completely agree’, scored with 0 to 5). A sum
score was made (range 0 to 45), and linear trans-
formed into a scale from zero to 100 [15]. A higher
score indicates a higher level of acceptance towards
shared-decision making.
3. Beliefs about OACA and their use
The validated Beliefs about Medicines
Questionnaire (BMQ-Specific) [18, 19] was
incorporated to assess the beliefs about the
necessity of the medication to control the disease
and the concerns about the potential negative
impact of the medication. The BMQ-Specific con-
sists of five items for the subscales ‘Necessity’, and
‘Concerns’. Both are scored on a 5-point Likert
scale (‘strongly disagree’ to ‘strongly agree’, scored
from 1 to 5) resulting in a score for the subscales
ranging from 5 to 25. BMQ-Specific was adapted
for use in HCPs by Lesuis et al. (Sint Maartenskli-
niek, Nijmegen, the Netherlands) and was trans-
lated into Dutch according to the inverse
translation method [20] by CB and LT. The Dutch
HCP version was authorised by the original first au-
thor R. Horne [18]. HCPs were categorized into
four attitudinal groups: accepting (high necessity,
low concerns), ambivalent (high necessity, high
concerns), indifferent (low necessity, low concerns)
and sceptical (low necessity, high concerns) with
the scale midpoint of 15 or above used as a cut-off
to define low and high beliefs [21].
4. Care usually provided in supporting adherence to
treatment with OACA
To assess the care provided in supporting adherence
to treatment with OACA, a list of care activities was
prepared. Point of departure of the list was the
Quality of Standard Care questionnaire as used by
the Bruin et al. [15, 16] to assess usual care in
supporting patients to adhere to anti-retroviral
therapy. The list was adapted to cancer care by the
research team consisting of three pharmacists, a
nurse, a psychologist and a health scientist, with
expertise in the field of medication adherence in
medical oncology and haematology. A total of 47 care
activities were listed. Items were divided into three
parts: activities carried out at the initiation of therapy,
activities carried out during follow-up appointments,
and activities which were not connected to specific
time-points. For each item, HCPs were asked to
indicate whether they had provided that particular
care (activity) during the last six months to the
majority of their patients. When the answer was
positive, this activity was calculated with one point in
the sum score. The minimum score is zero (when
none of the listed care activities usually performed),
the maximum score is 47 (when all 47 care activities
are usually performed).
The listed items were categorised into eight domains:
Knowledge, Awareness, Self-efficacy, Intention Formation,
Implementation, Social Support, Adverse Events Management
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and Facilitation. Each member of the research group inde-
pendently categorised the 47 care activities into one of the
eight domains. The categorization of the items was discussed
within the research group in two rounds until consensus was
reached. Table 1 gives an overview of the domains, its defini-
tions, and typically used techniques within the domain. The
categorization was not made with the intention to develop a
questionnaire that assesses eight domains, but was done to
organize all the activities.
Statistics
Respondent descriptive data were analysed as frequencies
(percentages) for categorical variables and as the median
and interquartile range (IQR) for continuous data. The
usual care sum scores of HCPs in the Netherlands and in
Belgium were compared for all professions by means of
the non-parametric Mann Whitney test for nurse practi-
tioners and the T-test for all other professions (with
normally distributed scores). Though the items listed
Associations between respondent characteristics and care
activities were assessed in univariate linear regression
analyses, with the usual care sum score as the dependent
variable. A multivariate linear regression was performed
using all HCPs’ characteristics with p < 0.25 in the univari-
ate analyses. A backward elimination procedure was used
where at each step the predictor with highest p-value was
dropped from the model until only significant predictors
remained. For all analyses, a two-tailed significance level
of 0.05 was used. P-values below this level were consid-
ered statistically significant. Statistical analysis was per-
formed with SPSS 22.0 for Windows (IBM Corp, Armonk,
NY, USA).
Results
Respondent characteristics
A total of 208 HCP (29% male) participated, of whom
107 were affiliated to 51 of 95 (54%) hospitals in the
Netherlands and 101 were affiliated to 26 of 59 (44%)
hospitals in Belgium. Of the participants 31.8% was
physician (15.9% medical oncologist, 15.9% haematolo-
gist), 28.8% nurse, 16.8% nurse practitioner and 22.6%
pharmacist. HCP characteristics and their scores on the
PAMQs, SDM-Q-doc, and BMQ are shown in Table 2.
Usual care provided in supporting adherence to OACA
treatment
Table 3 depicts for each of the 47 care activities the percent-
age of physicians, nurse practitioners, nurses and pharma-
cists who reported to perform this care activity in the last six
months in the majority of their patients. The Cronbach’s
alpha for the domains of care activities are: Knowledge: 0.836,
Awareness: 0.693, Self-efficacy: 0.886, Intention Formation:
0.754, Implementation: 0.548, Social Support: 0.519, Adverse
Events Management: 0.909 and Facilitation: 0.791. In the
Additional file 1: Table S1 they are presented by profession
as well. The median score and interquartile range per do-
main are shown in Table 4. The median usual care sum score
(range 0–47) was 24.0, 30.0, 24.5 and 11.0 for physicians,
nurse practitioners, nurses and pharmacists, respectively.
The median scores as percentage of the maximum score for
physicians, NPs, nurses and pharmacists, respectively, were:
Knowledge: 86, 100, 71 and 29%; Awareness: 75, 75, 63 and
0%; Self-efficacy: 60, 80, 50 and 0%; Intention Formation: 67,
100, 83 and 50%; Implementation: 25, 50, 25 and 0%; Social
Support: 67, 67, 67 and 0%; Adverse Events Management:
100, 100, 100 and 29%; Facilitation: 64, 73, 55 and 27%.
Table 1 Domains of Usual Care activities in supporting adherence to OACA
Domain Definition Typically used technique(s)
Knowledge Usual care activities focussing on the knowledge of patients
about their diseases and the medicines used for treatment,
excluding knowledge related to adverse events
- providing information
- increase patient understanding
Awareness Usual care activities aimed to increase the awareness of
patients with respect to non-adherence to treatment and
consequences of non-adherence
- risk communication
- giving feedback on patients’ behaviour
Self-efficacy Usual care activities that focus on self-efficacy; a patient’s
belief in her/his ability in succeeding to adhere to treatment
- the planning of coping responses like discussing
barriers and finding ways to overcome them
Intention Formation Usual care activities which focus on fostering the intention
to adhere by planning how and when to take the medication
- tailoring the medication schedule
Implementation Usual care activities which focus on the effective implementation
of the intended use of medication
- stimulating the use of cues
Social Support Usual care activities that provide patients with professional
social support with respect to the correct use of their medication
- giving social support
Adverse Events Management Usual care activities which focus on patients’ management
of adverse events
- providing information about adverse events
- facilitating coping with adverse events
Facilitation Usual care activities which facilitate a correct use of
medication and which are not categorized in one
of the other domains
- reducing environmental barriers
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Belgium versus the Netherlands
Table 5 shows the mean usual care sum scores of the
different professions for the Netherlands and Belgium
separately. Belgian physicians had a higher UC sum score
compared to their Dutch colleagues (31.0 vs. 22.7) (p =
0.043). Dutch nurses and pharmacists had a higher UC
sum score than their Belgian colleagues (35.0 vs. 28.0 and
18.5 vs. 3.0, respectively p < 0.001 and p =0.026).
Associations with usual care provided in supporting
adherence to treatment with OACA
Univariate and multivariate associations with the usual
care sum score are presented in Table 6. Compared with
physicians, the usual care sum score of nurse practi-
tioners was higher (beta 4.2; 95%CI [0.4, 8.0], p = 0.031)
and the usual care sum score of pharmacists was lower
(beta -12.7; 95%CI [-16.0, -9.3], p < 0.001). Perceptions of
adherence management were related to the care pro-
vided. A more positive score on the perceptions ques-
tions (higher PAMQs sum score) was significantly
related to a higher usual care sum score (beta 3.2; 95%CI
[2.3, 4.2], p < 0.001). Higher scores on the PAMQ Insight
into adherence, Patients’ communication, Capability to
influence and Insight into causes were significantly re-
lated with a higher usual care sum score (p < 0.02). In
the multivariate linear regression analyses the following
HCPs’ characteristics were significantly associated with
the usual care sum score: Profession (p < 0.001), Country
(the Netherlands as reference) (beta -3.5; 95%CI[-5.8, -
1.2], p = 0.003), gender (male as reference) (beta 2.8;
95%CI [0.1–5.4], p = 0.042) and PAMQs sum score (beta
2.3; 95%CI [1.4, 3.1], p < 0.001). The beliefs about OACA
and the physicians’ perceptions about SDM were not as-
sociated with the usual care sum score.
Discussion
The present study shows that HCPs considered them-
selves to actively support their patients in adhering to
treatment with OACA by using a wide range of activ-
ities. The 47 listed care activities were all, to a greater or
lesser extent, performed in clinical practice in the
Netherlands and Belgium. However, in certain areas ac-
tivities were carried out only to a limited extent.
The domain Knowledge consists of care activities that
are mainly performed at the start of treatment. Providing
information is required since patients need to under-
stand the usefulness of a particular drug in order to con-
sent to treatment. Patient education is often used in
interventions to enhance medication adherence [22, 23].
However, to achieve awareness of the importance of ad-
hering to OACA treatment the impact of non-adherence
should be made clear. Most HCPs reported to discuss
both the importance of adherence and the consequences
of non-adherence. This is in line with their scores on the
Table 2 Characteristics of health care providers N = 208
All NL Be
N = 208 N = 107 N = 101
Gender (%)
Male 29.3 33.6 24.8
Female 70.7 66.4 75.2
Profession (%)
Medical oncologist 15.9 10.3 21.8
Haematologist 15.9 26.2 5.0
Nurse practitioner 16.8 17.8 15.8
Nurse 28.8 21.5 36.6
Pharmacist 22.6 24.3 20.8
Work experience (yr)
Median 16 16 17
Range 1–46 2–46 1–40
Type of hospital (%)
Academic 29.6 22.4 37.4
Non-academic 70.4 77.6 62.6
Number of hospitals 87 51 36
Specialisation (%)
Haematology 30.6 38.0 22.6
Oncology 69.4 62.0 77.4
Adherence (PAMQs) (%)
Insight into adherence 41.8 43.9 39.6
Patients’ communication 43.8 45.8 41.6
Capability to influence 82.2 86.0 78.2
Knowledge of consequences 78.8 75.7 82.2
Insight into causes 68.3 69.2 67.3
PAMQs sum score (0–5)
Median 3.0 3.0 3.0
IQR 2.0–4.0 2.0–4.0 2.0–4.0
SDMa-score (0–100) 82.2 84.4 80.0
BMQ-Specific (mean ± sd)
Necessity 18.3 ± 3.0 17.8 ± 2.9 18.7 ± 3.0
Concerns 13.4 ± 2.6 12.9 ± 2.6 13.9 ± 2.5
N-C differential 4.9 ± 3.7 4.9 ± 3.8 4.8 ± 3.7
BMQ-group (%)
Accepting 58.3 61.3 55.0
Ambivalent 31.1 24.5 38.0
Indifferent 8.3 11.3 5.0
Sceptical 2.4 2.8 5.0
Abbreviations: NL the Netherlands, Be Belgium, yr year, PAMQs, HCP’s
Perceptions of Adherence Management Questions, IQR interquartile range,
SDM-score sum score of the Shared Decision Making-doc-Questionnaire, BMQ
Beliefs about Medicines Questionnaire
aSDM assessed only for physicians
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Table 3 Usual Care activities in supporting adherence to OACA N = 208
physician NP nurse pharmacist
NL 39a Be 27a NL 19a Be 16a NL 23a Be 37a NL 26a Be 21a
% % % % % % % %
Knowledge PoT
Provide information on the disease S 100.0 100.0 100.0 100.0 82.6 70.3 23.1 9.5
Provide information on the expected effect(s) of the drug S 100.0 100.0 100.0 75.0 86.4 59.5 38.5 19.0
Discuss the action of the drug S 92.3 100.0 100.0 75.0 81.8 48.6 57.5 23.8
Hand out brochures or written information about the
disease and/or medication used for treatment
S 62.2 74.1 84.4 87.5 87.6 54.1 84.6 28.6
Discuss when the first effect of the medication can be expected S 100.0 100.0 84.4 56.3 72.7 37.8 26.9 14.3
Monitor and/or discuss possible interactions with other
medicines or foods
S 75.7 96.3 100.0 87.5 73.9 62.2 96.2 33.3
Discuss (changes in) sexuality G 35.1 28.0 82.4 50.0 47.4 35.1 0.0 0.0
Awareness
Discuss the importance of treatment adherence S 84.2 88.5 82.4 93.8 85.0 78.4 64.0 28.6
Discuss the consequences of non-adherence (to treatment) S 64.9 80.8 70.6 68.8 65.6 56.8 32.0 23.8
Ask the patient if he/she has missed one or more doses F 68.4 60.0 94.1 68.8 78.9 59.5 12.0 19.0
Discuss the use and results of the Medication Event
Monitoring System (MEMS)
F 2.8 8.0 6.3 6.3 5.3 5.4 4.0 0.0
Self-efficacy
Encourage patients to timely plan the intake of medicines
during holidays and weekends
S 52.8 53.8 58.8 56.3 47.4 40.5 24.0 19.0
Discuss potential barriers regarding treatment adherence S 51.4 61.5 68.8 56.3 65.0 45.9 28.0 23.8
Discuss possible ways to overcome potential barriers
regarding treatment adherence
S 51.4 65.4 76.5 62.5 65.0 40.5 32.0 23.8
Inquire after barriers regarding treatment adherence F 55.3 64.0 82.4 68.8 57.9 45.9 20.0 14.3
Discuss ways to overcome potential barriers regarding
treatment adherence
F 51.4 64.0 76.5 62.5 57.9 35.1 20.0 14.3
Intention Formation
Discuss the scheduled duration of medication treatment S 100.0 100.0 100.0 81.3 77.3 45.9 46.2 14.3
Explain how often the medicine should be taken.
If necessary, explain the treatment schedule
S 84.6 100.0 100.0 93.8 91.3 89.2 96.2 52.4
Discuss the intake of the medicines relative to that of
meals and why
S 60.0 88.9 100.0 93.8 91.3 86.5 92.3 47.6
Discuss what to do if there is vomiting shortly after
ingestion of the medicine
S 41.7 85.2 88.9 93.8 81.8 73.0 38.5 28.6
Explain what to do if a dose is missed S 51.4 76.9 94.1 100.0 94.7 64.9 48.0 38.1
Development of an individual written medication schedule S 17.1 42.3 75.0 87.5 52.6 48.6 32.0 23.8
Implementation
Identify daily routines and encourage patients to align
the taking of medicines with their routines
S 45.9 69.2 100.0 81.3 90.0 62.2 28.0 19.0
Encourage patients to use a seven day pillbox S 13.5 23.1 50.0 50.0 21.1 43.2 16.0 19.0
Encourage patients to use the Medication Event
Monitoring System (MEMS)
S 0.0 11.5 12.5 6.3 0.0 5.4 4.0 4.8
Encourage patients to use alarm devices for properly
timing their medication intake
S 5.6 19.2 58.8 37.5 21.1 29.7 12.5 14.3
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PAMQs where the majority of HCPs stated to have ad-
equate knowledge about the consequences of non-
adherence [14]. Care to maintain awareness, as reflected
by the item ‘ask if a dose is missed’, is provided less fre-
quently, particularly in Belgium. A study on nursing
practices for patients on OACA treatment in Japan also
found that nurses were less likely to ask patients with re-
fills adherence-related questions [24]. Only a minority of
HCPs performed usual care activities within the domain
Self-efficacy. It is known that self-efficacy is an important
factor influencing medication adherence and adequate
self-management. It is addressed in theoretical behavioural
frameworks [25] as well as in medication adherence on-
cology research [26, 27]. To raise self-efficacy (expected)
barriers to optimal adherence must be identified and
strategies to overcome these obstacles should be dis-
cussed. This requires HCPs to directly focus on medica-
tion adherence. Clear instructions are needed to finish the
Intention Formation. Instructing patients about the regu-
lar intake is reported by almost all HCPs, but information
to handle specific situations, for example what to do in
case of a missed dose or in case of vomiting shortly after
ingestion, is provided less frequently. This item clearly
needs more attention. Activities classified in the domain
Implementation also received relatively poor attention.
Care activities within this domain focus on cues that are
relevant to prevent unintentional non-adherence. Since
adherence decreases by treatment duration [10, 28], care
activities aimed at the continuation of a correct use are
particularly relevant in long term treatment. In view of the
Table 3 Usual Care activities in supporting adherence to OACA N = 208 (Continued)
Social Support
Involve partner and/or relatives in the treatment S 86.8 84.6 87.5 87.5 85.0 81.1 32.0 23.8
Encourage patients to organize social support G 55.6 40.0 58.8 50.0 60.0 48.6 4.0 0.0
Refer a patient to a patients’ association G 73.7 24.0 76.5 43.8 47.4 21.6 4.0 0.0
Adverse Events Management
Discuss the common adverse events of the drug S 94.9 100.0 100.0 87.5 87.0 83.8 61.5 28.6
Discuss options to mitigate the impact of adverse
events (at start of treatment)
S 70.3 96.3 97.1 93.8 85.0 83.8 48.9 33.3
Discuss the possibility of dose adjustment if adverse events occur S 86.8 96.3 77.8 68.8 77.3 62.2 26.9 28.6
Inquire after (perceived) adverse events of treatment F 100.0 100.0 100.0 100.0 89.5 83.8 72.0 23.8
Inquire after the severity of the adverse events F 100.0 100.0 100.0 93.8 89.5 86.5 56.0 23.8
Discuss options to mitigate the impact of adverse events
(during treatment)
F 89.5 96.0 100.0 87.5 94.7 73.0 52.0 28.6
Give the patient a telephone number and tell who to
contact in the case of adverse events
G 82.9 88.0 100.0 93.8 94.7 73.0 24.0 19.0
Facilitation
Explain how and where the product is available S 81.6 85.2 94.4 87.5 90.5 59.5 76.9 42.9
Discuss drug storage recommendations S 16.7 55.6 64.7 81.3 70.0 62.2 88.5 81.0
Give feedback about treatment efficacy F 100.0 100.0 82.4 56.3 73.7 35.1 16.0 9.5
Inquire after positive effects of treatment F 100.0 92.0 76.5 86.3 89.5 59.5 28.0 19.0
Ensure the timely transfer of medication information
to other health care providers
G 86.5 72.0 62.5 56.3 60.0 29.7 100.0 23.8
Call the patient after the start of treatment to ask
about experiences
G 11.8 4.0 64.7 37.5 68.4 18.9 8.0 0.0
Give the patient a telephone number and tell who
to contact in case of problems with treatment adherence
G 69.4 64.0 82.4 93.8 78.9 54.1 28.0 19.0
Inform the patient about 24 hour availability of assistance G 91.7 76.0 100.0 62.5 90.0 64.9 28.0 23.8
Intensify the number of follow-up visits if patients have
problems with treatment adherence
G 45.9 28.0 58.8 43.8 42.1 18.9 8.0 9.5
Refer patients to another health care provider for (co-)
treatment (e.g., in the case of adverse events)
G 57.9 64.0 70.6 56.3 47.4 40.5 40.0 14.3
Refer to another health care provider in case of
(suspected) psychosocial problems
G 75.7 80.0 88.2 75.0 78.9 75.7 0.0 14.3
Abbreviations: OACA oral anticancer agents, NL the Netherlands, Be Belgium, PoT point of time of the activity, S at start of treatment, F during follow-up visits, G
general activity which is not attached to a time-point, NP nurse practitioner
amissings excluded from analyses
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current progress in selecting patients that will respond on
OACA treatment, the number of patients on long-term
OACA treatment is likely to increase considerably. Thus,
there is a growing necessity to support on-going optimal
use of OACA. Patients with support from their social
environment are generally more adherent than those with
insufficient support [29, 30]. Any opportunity to
strengthen social support should not be missed. Adverse
events generally have the full attention of HCPs. Most
physicians, nurse practitioners and nurses performed all
care activities within this domain. This finding is not sur-
prising, as in oncology (serious) adverse events frequently
occur. Adverse events may substantially impinge on the
quality of life [29] and are related to non-adherence and
early discontinuation of OACA use [10, 27, 30]. All physi-
cians reported to inquire after experienced adverse events
and their severity. In the case of more severe adverse
events physicians must adjust OACA dosing regimens in
an individual manner. For some OACA this can be ac-
complished without compromising efficacy [31, 32].
Obtaining information on the occurrence of adverse
events and how they were experienced, as well as attempts
to alleviate their symptoms are therefore common activ-
ities in oncology care. It is well known that unpleasant ex-
periences regarding adverse events are associated with a
lower level of medication adherence and higher levels of
treatment discontinuation [4, 10]. The last domain, Facili-
tation, includes a variety of care activities. With respect to
certain items there are striking differences between Bel-
gian and Dutch HCPs. All Dutch pharmacists reported to
ensure the timely transfer of medication information to
other HCPs, whereas this is usual care for only a quarter
of their Belgian colleagues. This suggests that there is a
difference in the national organisation of information ex-
change between HCPs. It is interesting to note that in
both countries the majority of HCPs usually does not in-
tensify follow-up visits in the case that patients have prob-
lems with medication adherence.
Not all care activities can be and should be provided
to all patients. Care should be tailored to the each pa-
tients’ situation and needs. On the other hand, all care
domains appear to be relevant in maintaining medica-
tion adherence. We therefore recommend to cover all
domains. Our list with care activities classified in do-
mains can be used as a starting point to reflect on the
level of care in one’s own clinical practice. Furthermore,
in intervention studies researchers should be aware of
Table 4 Usual Care in supporting adherence to OACA: median scores per domain
Awareness Self-efficacy Intention
Formation
Implemen- tation Social
Support
Adverse Events
Management
Facilitation UC sum
score
Range: 0–7 0–4 0–5 0–6 0–4 0–3 0–7 0–11 0–47
Physicians
Median 6.0 3.0 3.0 4.0 1.0 2.0 7.0 7.0 24.0
IQR 5–6 2–3 1–5 3–5 0–1 1.5–2 6–7 6–8 19.3–28.8
% median score 86% 75% 60% 67% 25% 67% 100% 64% 51%
NPs
Median 7.0 3.0 4.0 6.0 2.0 2.0 7.0 8.0 30.0
IQR 6–7 2–3 1.3–5 6–6 1–3 2–3 6–7 7–10 25.5–34.0
% median score 100% 75% 80% 100% 50% 67% 100% 73% 64%
Nurses
Median 5.0 2.5 2.5 5.0 1.0 2.0 7.0 6.0 24.5
IQR 3–6 1–3 0–5 3–6 1–2 1–3 5.3–7 4–9 15.8–31.0
% median score 71% 63% 50% 83% 25% 67% 100% 55% 52%
Pharmacists
Median 2.0 0 0 3.0 0 0 2.0 3.0 11.0
IQR 0–3.3 0–2 0–2 1–4 0–1 0–1 0–6 1–6 3.5–17.0
% median score 29% 0% 0% 50% 0% 0% 29% 27% 23%
Abbreviations: UC usual care, IQR interquartile range, NPs nurse practitioners
Table 5 Usual Care in the Netherlands versus Belgium
NL Be NL vs. Be
N UC-sum N UC-sum p
Physician 27 22.7 25 31.0 0.043*
NP 13 38.0 16 36.5 0.263
Nurse 17 35.0 37 28.0 <0.001*
Pharmacist 24 18.5 21 3.0 0.026*
Abbreviations: vs versus, NL the Netherlands, Be Belgium, UC-sum mean sum
score of usual care activities (0-47); NP nurse practitioner
*significant (p < 0.05)
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the need to accurately describe both the standard or
usual care. In clinical trials too often the control arm
has been poorly defined [33, 34], resulting in uncertainty
about the effects of the intervention studied [15, 33].
The differences in usual care activities between both
studied countries reinforce this need.
The care provided usually to support medication adher-
ence reported in this study differed among professions
and country. Whereas in Belgium physicians performed
more care activities to support adherence to OACA treat-
ment, in the Netherlands a higher percentage of nurses
and pharmacists reported to perform these activities. In
line with their specialization, training in education, focus
on self-management support and time spent on patient-
contact, both in Belgium and in the Netherlands nurse
practitioners performed the widest range of care activities.
The impact of nurse practitioners on the quality of care in
oncology has been shown previously [34, 35]. On the
other hand, there was a large difference in care provided
by pharmacists in both countries, with Dutch pharmacists
performing considerably more activities than their Belgian
colleagues. An explanation might be that in Belgium
OACA are dispensed by hospital pharmacists, whereas in
the Netherlands OACA are dispensed by specialized phar-
macies in the outpatient clinics which resemble commu-
nity pharmacies and are staffed by pharmacists who are
trained in patient contact. In addition, Dutch pharmacists
generally have access to a patients’ list of (co-)medication
due to integrated electronic data services. Nevertheless, in
both countries pharmacists only play a limited role in
Table 6 Associations with Usual Care sum score N = 180
univariabel multivariabel
beta 95% CI p-value beta 95% CI p-value
Gender (male) 1.97 [–1.35, 5.28] 0.244 2.75 [0.096, 5.40] 0.042
Profession <0.001* <0.001*
Physician as reference:
Nurse Practitioner 4.19 [0.38, 8.01] 0.031* 3,2 [–0.43, 6.83] 0.084
Nurse –1.60 [–4.80, 1.59] 0.324 –0,54 [–3,64, 2.55] 0.729
Pharmacist –12.69 [–16.04,–9.34] <0.001* –10,9 [–14.2,–7.72] < 0.001
Work experience (yr) –0.03 [–0.17, 0.11] 0.673
Type of hospital (academic) –3.20 [–6.45, 0.06] 0.054
Specialisation (oncology) –2.36 [–5.80, 1.09] 0.178
Country (the Netherlands) –2.51 [5.50, 0.48] 0.100 –3,51 [–5.81,–1.21] 0.003*
Adherence (PAMQs)
Insight in adherence 6.80 [3.93, 9.68] <0.001*
Patients’ communication 9.32 [6.62, 12.01] <0.001*
Capability to influence 5.78 [2.08, 9.47] 0.002*
Knowledge of consequences 3.60 [–0.04, 7.24] 0.053
Insight in causes 3.70 [0.59, 6.81] 0.020*
PAMQs sum score 3.23 [2.26, 4.19] <0.001* 2,26 [1.41, 3.11] <0.001*
SDM scorea –0.00 [–0.09, 0.09] 0.973
BMQ-Specific
Necessity –0.15 [–0.65, 0.36] 0.565
Concerns –0.074 [–6.94, 0.55] 0.814
N-C differential –0.07 [–0.48, 0.35] 0.753
BMQ-group 0.972
Accepting as reference:
Ambivalent –3.34 [–3.72, 3.05] 0.844
Indifferent 0.32 [–5.45, 6.08] 0.866
Sceptical –2.22 [–12.55, 8.11] 0.680
Abbreviations: OR odds ration; 95%CI, 95% confidence interval, yr year, PAMQs Perceptions of Adherence, Management Questions, SDM-score sum score of the
Shared Decision Making-doc-Questionnaire, BMQ Beliefs about Medicines Questionnaire, N-C Necessity-Concerns
aSDM only assessed for physicians
* = significant
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supporting adherence to OACA as compared to other
HCPs. Since they are medicine experts and are well expe-
rienced in supporting medication adherence in patients
with chronic diseases, greater involvement of pharmacists
in the multidisciplinary teams may improve adherence
care in (haemato-)oncology [36].
Successful care with regard to medication adherence,
should not be dependent on individual HCPs but sup-
ported by a proper organization of care. Recent studies in
other countries on current practices to support patients
treated with OACA have revealed considerable variation
in the extent and quality of the care provided [24, 37, 38].
A large survey among nurses in the US showed that in
about half of practices policies and procedures to support
patients were lacking and that interdisciplinary communi-
cation was inadequate [37]. A study among Spanish oncol-
ogy pharmacists also demonstrated that adherence
practices for oral OACA treatment were only imple-
mented in about half of hospitals [38]. A nurse-based sur-
vey in Japan indicated that adherence-related practices
varied and were associated with nurse’s background, type
of treatment and healthcare system-related factors [24]. In
line with the results of the present study, medication ad-
herence management in patients treated with OACA as
part of the care that is usually provided clearly shows op-
portunities for improvement.
For all HCPs participating in the present study, there
was a strong relationship between the perceptions of
medication adherence management and the number of
care activities performed. Although the majority of HCPs
stated to have adequate knowledge of medication adher-
ence management [14], the association suggests that
promoting HCPs’ awareness and increasing their know-
ledge about adherence management will improve the
usual care that is provided to support patients in adher-
ing to OACA treatment.
There are strengths and limitations to discuss. The
present study provides an extensive survey of care activ-
ities performed by a variety of HCPs including physi-
cians, nurse practitioners, nurses and pharmacists aimed
to support adherence to OACA treatment. The list of 47
items was literature based and completed with input
from medical oncologists, haematologists, nurse practi-
tioners, nurses, pharmacists and researchers experienced
in performing care activities related to promoting adher-
ence to OACA treatment from two countries. A limita-
tion to address is that these care activities were reported
for patients using OACA for all types of cancer. Patients
using long-term medication need to be supported in a
different manner than patients with shorter life expect-
ancies. Another limitation is that the response rate could
not be calculated. Information on the number of HCPs
reached with the postings and the number of the
reached HCPs involved in the care for patients using
OACA was not available. However, the respondents
were employed in no less than 87 hospitals in the
Netherlands and Belgium. Another limitation is the po-
tential selection bias as the result of the methods ap-
plied. The questionnaire might have been filled out
mainly by HCPs with awareness of the importance of
medication adherence and/or those actively involved in
the management of medication adherence. Furthermore,
answers may be overstated by the tendency to give so-
cially desirable answers. It is therefore not unlikely that
in daily practice the medication adherence care activities
are less extensively performed than reported. Finally, it
would also be interesting to study these care activities
from the patients’ perspective.
Conclusions
Although HCPs reported to perform a wide range of
care activities, certain domains related to the manage-
ment of medication adherence in patients treated with
OACA were given less attention. Activities related to pa-
tient knowledge and adverse event management were re-
ported most frequently but activities aimed to support
self-efficacy and maintain adherence during ongoing use
were frequently missed. HCPs should improve care by
addressing adherence directly e.g., by questioning pa-
tients’ (expected) barriers and discussing strategies to
overcome them, by asking after missed doses and offer-
ing (electronic) reminders to support long-term medica-
tion adherence. Enhancing HCP’s perceptions of
management of adherence is likely to have a positive ef-
fect on the quality of the care they provide to their pa-
tients. A multidisciplinary approach is recommended in
which the role of the pharmacist could be expanded.
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